A randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial that evaluated the efficacy, safety, and tolerability of lorundrostat in participants with uncontrolled hypertension, including treatment-resistant hypertension.
A randomized, double-blind, placebo-controlled, parallel-arm, multicenter, phase 3 trial that evaluated the blood pressure-lowering effects of lorundrostat in participants with uncontrolled hypertension, including treatment-resistant hypertension, taking 2-5 antihypertensive medications (one of which had to be a thiazide or thiazide-like diuretic).
A randomized, double-blind, placebo-controlled, parallel-arm, multicenter, pivotal phase 2 trial that evaluated the blood pressure-lowering effect of lorundrostat administered on a background of a standardized antihypertensive medication regimen in participants with uncontrolled hypertension, including treatment-resistant hypertension.
An ongoing open-label extension study to evaluate the long-term efficacy, safety, and tolerability of lorundrostat in participants with uncontrolled hypertension, including treatment-resistant hypertension.
A randomized, crossover, double-blind, placebo-controlled, phase 2 study that evaluated the efficacy and safety of lorundrostat alone and in combination with sodium-glucose cotransporter-2 inhibitors in participants with hypertension and chronic kidney disease with albuminuria.
A phase 2, multicenter, randomized, double-blind, placebo-controlled, crossover study that evaluated the efficacy and safety of lorundrostat in participants with moderate to severe obstructive sleep apnea and hypertension.
Lorundrostat is an aldosterone-reduction therapy with highly selective inhibition of aldosterone synthase.
A randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial that evaluated the efficacy, safety, and tolerability of lorundrostat in adults with uncontrolled hypertension, including treatment-resistant hypertension.
